迈瑞医疗 (300760.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(迈瑞医疗)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2022年第三季度2022年第二季度2022年第一季度2021年第四季度2021年第三季度2021年第二季度2021年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 7,940,254,590.008,412,467,085.006,943,108,994.005,878,068,543.006,613,164,642.006,997,297,898.005,781,049,735.00
 营业收入(元) 7,940,254,590.008,412,467,085.006,943,108,994.005,878,068,543.006,613,164,642.006,997,297,898.005,781,049,735.00
二、营业总成本(元) 4,873,324,181.004,933,671,206.004,630,030,820.004,551,739,298.004,095,493,324.004,041,914,995.003,978,391,572.00
 营业成本(元) 2,808,330,239.003,085,034,103.002,422,990,195.002,172,906,535.002,270,407,082.002,377,480,109.002,021,921,490.00
 研发费用(元) 737,297,164.00646,137,211.00703,945,494.00894,819,681.00567,885,079.00473,555,032.00587,917,833.00
 营业税金及附加(元) 95,839,706.0078,476,139.0079,449,251.0066,572,214.0078,330,388.0076,828,522.0060,257,780.00
 销售费用(元) 1,178,429,824.001,079,086,175.001,072,950,119.001,155,327,096.00968,564,340.00923,438,115.00951,618,192.00
 管理费用(元) 312,078,416.00260,435,487.00358,376,634.00262,104,171.00253,236,113.00265,676,410.00324,666,396.00
 财务费用(元) -258,651,168.00-215,497,909.00-7,680,873.009,601.00-42,929,678.00-75,063,193.0032,009,881.00
  其中:利息费用(元) 2,807,399.002,555,050.002,258,677.002,374,223.002,085,118.00--
  其中:利息收入(元) 78,736,530.0085,872,762.0088,598,038.0093,002,302.0090,883,199.00122,585,849.00100,853,646.00
 资产减值损失(元) -19,749,751.00-8,013,755.00-20,503,792.00-65,312,579.00-29,828,868.00-32,255,022.00-4,337,760.00
 信用减值损失(元) -3,551,378.00-1,664,433.00-5,030,639.0034,239,789.00-4,692,496.00-29,410,469.005,677,145.00
三、其他经营收益
 加:公允价值变动收益(元) --29,203,624.007,825,435.0014,314,900.002,314,728.00--
 加:投资收益(元) -1,401,170.00-1,403,482.00-1,172,501.002,901,015.00-561,220.00369,647.00-1,897,961.00
  其中:对联营企业和合营企业的投资收益(元) -1,401,170.00-1,403,482.00-1,172,501.002,901,015.00-561,220.00369,647.00-1,897,961.00
 资产处置收益(元) 5,311,602.007,423,747.00-6,659,319.001,214,624.001,266,438.001,298,921.00285,901.00
 其他收益(元) 166,287,221.00157,793,189.00113,998,291.00156,831,751.00186,573,056.00128,618,276.00102,816,332.00
四、营业利润(元) 3,213,826,933.003,603,727,521.002,401,535,649.001,470,518,745.002,672,742,956.003,017,253,461.001,905,201,820.00
 加:营业外收入(元) 11,938,900.0010,904,898.005,112,409.006,484,198.005,369,555.008,009,029.003,378,142.00
 减:营业外支出(元) 5,715,184.0012,117,309.00941,951.0043,353,481.0010,959,626.0011,641,834.005,918,132.00
五、利润总额(元) 3,220,050,649.003,602,515,110.002,405,706,107.001,433,649,462.002,667,152,885.003,013,620,656.001,902,661,830.00
 减:所得税费用(元) 404,550,599.00419,203,029.00298,733,425.0094,930,304.00347,327,039.00383,652,279.00187,129,341.00
六、净利润(元) 2,815,500,050.003,183,312,081.002,106,972,682.001,338,719,158.002,319,825,846.002,629,968,377.001,715,532,489.00
(一)按经营持续性分类
  持续经营净利润(元) 2,815,500,050.003,183,312,081.002,106,972,682.001,338,719,158.002,319,825,846.002,629,968,377.001,715,532,489.00
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 2,814,681,784.003,182,580,387.002,105,071,901.001,338,670,399.002,318,453,562.002,629,393,304.001,715,036,341.00
  少数股东损益(元) 818,266.00731,694.001,900,781.0048,759.001,372,284.00575,073.00496,148.00
 扣除非经常性损益后的净利润(元) 2,756,585,765.003,174,908,759.002,072,184,897.001,306,222,581.002,234,808,098.002,613,659,941.001,695,726,614.00
七、每股收益
 一、基本每股收益(元) 2.332.631.741.111.912.161.41
 二、稀释每股收益(元) 2.332.631.741.111.912.161.41
八、其他综合收益(元) 93,446,642.00112,945,106.00-81,520,698.00-186,651,377.00-72,548,234.00-35,722,938.007,760,113.00
 归属于母公司股东的其他综合收益(元) 93,446,642.00112,945,106.00-81,520,698.00-186,651,377.00-72,548,234.00-35,722,938.007,760,113.00
九、综合收益总额(元) 2,908,946,692.003,296,257,187.002,025,451,984.001,152,067,781.002,247,277,612.002,594,245,439.001,723,292,602.00
 归属于母公司所有者的综合收益总额(元) 2,908,128,426.003,295,525,493.002,023,551,203.001,152,019,022.002,245,905,328.002,593,670,366.001,722,796,454.00
 归属于少数股东的综合收益总额(元) 818,266.00731,694.001,900,781.0048,759.001,372,284.00575,073.00496,148.00
公告日期 2022-10-282022-08-202022-04-202022-04-202021-10-202021-08-262021-04-29
审计意见(境内) 标准无保留意见

前瞻产业研究院